CD47 Antigen Inhibitors Market Forecast

• The CD47 Antigen Inhibitors Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• CD47 is a transmembrane protein in CD47 Therapeutics Market that acts as a high affinity signaling receptor for the secreted protein thrombospondin-1 (THBS1) and the counter-receptor for signal regulatory protein-α (SIRPA, SIRPα) and SIRPγ (SIRPG). 
• CD47 inhibitors work by targeting the CD47 protein, which is commonly found on the surface of cancer cells. CD47 acts as a "don't eat me" signal, preventing the immune system's macrophages from engulfing and destroying these cancerous cells.
• When a CD47 inhibitor binds to CD47, it effectively blocks this signal, allowing the immune system's macrophages to recognize and engulf the cancer cells. This process is part of the body's innate immune response, and by disrupting the CD47-CD47 receptor interaction, CD47 inhibitors can potentially enhance the immune system's ability to recognize and eliminate cancer cells.
• CD47 overexpression is found to be associated with poor prognosis in leukemia, non-Hodgkin's lymphoma, bladder cancer, breast cancer, and other cancers.
• At present, regulatory bodies have not approved any therapies specifically targeting CD47 inhibitors. However, several CD47 inhibitors are currently being evaluated in clinical trials. An example is ALX Oncology’s Evorpacept which is in Phase II/III for the treatment of Gastric/Gastroesophageal Junction Cancer, and in Phase II for Head and Neck Cancer and is anticipated to receive approval during the forecast period.
• ALX Oncology has collaborated with other major pharma companies such as Merck, Lilly, and others for evaluating Evorpacet in combination with various drugs such as KEYTRUDA, CYRAMZA, ZANIDATAMAB, and others.
• Gilead Sciences' investigational anti-CD47 monoclonal antibody, Magrolimab, had garnered significant attention with FDA designations like Breakthrough Therapy designation for the treatment of Myelodysplastic Syndrome (MDS) and was the most advanced CD47 targeted therapy in development. However, recently, all Magrolimab studies in MDS and Acute Myeloid Leukemia (AML) were halted by the Food and Drug Administration due to observed futility and an elevated risk of mortality.
• In July 2022, the US FDA granted Orphan Drug Designation to Evorpacept for Acute Myeloid Leukemia (AML), and in August 2022, Fast Track Designation for Head and Neck Squamous Cell Carcinoma.
• In June 2024, SL-172154 received FDA Orphan Drug Designation in Acute Myeloid Leukemia. SL-172154 is an investigational activity-regulated cytoskeleton-associated protein (ARC) fusion protein that inhibits the checkpoint interaction of CD47/SIRPα and activates the CD40 costimulatory receptor. The agent is designed to boost the antitumor immune response in patients with advanced cancer.
• ALX Oncology, Phanes Therapeutics, Shattuck Labs, and several other companies are currently engaged in the development and production of selective CD47 inhibitors, which have the potential to significantly impact and enhance the CD47i market.

Your Path to Market Mastery Starts Here: Get Your Detailed Sample Page Today and Elevate Your Strategic Decisions @ CD47 Targeting Therapeutics Market

DelveInsight’s “CD47 Targeting Therapeutics Market Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the CD47 inhibitors, historical and forecasted epidemiology, competitive landscape as well as the CD47 inhibitors therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The CD47 Inhibitors Drug Clinical Trials Report provides current treatment practices, emerging drugs, market share of individual therapies, current and forecasted 7MM CD47 inhibitors market size from 2020 to 2034. The CD47 Therapeutics Market Report also covers current CD47 inhibitors treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

CD47 Targeting Therapeutics Market Understanding and Treatment Algorithm

CD47 (Cluster of Differentiation 47) also known as integrin-associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene in the CD47 Therapeutics Market. It is found in both healthy and malignant cells. It regulates macrophage-mediated phagocytosis by sending a "don't eat me" signal to the signal regulatory protein alpha (SIRPα) receptor. 

CD47 is a high-affinity signaling receptor for the secreted protein thrombospondin-1 (THBS1) and the counter-receptor for signal regulatory protein-α (SIRPA, SIRPα) and SIRPγ (SIRPG). 

CD47 interaction with SIRPα serves as a marker of self to innate immune cells and thereby protects cancer cells from phagocytic clearance. Higher CD47 correlates with a poor prognosis in some cancers, and therapeutic blockade can suppress tumor growth by enhancing innate antitumor immunity. 

CD47 is involved in regulating immune responses, and when it is overexpressed, it can help cancer cells evade detection and destruction by the immune system. CD47 expressed on cytotoxic T cells, dendritic cells, and NK cells mediates inhibitory THBS1 signaling that further limits antitumor immunity. 

CD47 Therapeutics Market Treatment

CD47-targeted therapies, including antibody-based therapies, CAR T-cell therapy, and combination therapies, have shown promise in enhancing anti-tumor immunity and improving clinical outcomes.

CD47-targeted immunotherapies aim to enhance anti-tumor immunity and improve clinical outcomes by disrupting the “don’t eat me” signal between CD47 (on cancer cells) and SIRPα (on myeloid cells). One of the approach is to use blocking antibodies or small molecules that inhibit this interaction, leading to increased phagocytosis of cancer cells by macrophages and promoting an anti-tumor immune response.

Preclinical studies and early clinical trials have shown promising results with CD47 inhibitors in various types of cancer, including leukemia, lymphoma, breast cancer, and others. 

CD47 Inhibitors Drug Analysis

The drug chapter segment of the CD47 inhibitors reports encloses a detailed analysis of CD47 inhibitors marketed drugs and late-stage (Phase II/III, Phase II, and Phase I/II) pipeline drugs. It also helps understand the CD47 inhibitors' clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

CD47 Targeting Therapeutics Marketed Drugs

At present, regulatory bodies have not approved any therapies specifically targeting CD47 inhibitors.

CD47 Inhibitors Emerging Drugs

Evorpacept (ALX148): ALX Oncology

Evorpacept is a highly differentiated anti-CD47 blocker with an inactive Fc effector function. In clinical studies, evorpacept has demonstrated a substantially better safety profile to date than competing anti-CD47 molecules with an active Fc. This favorable safety profile allows for higher dosing and minimal overlapping toxicity in the combination setting for which it was designed. 

Evorpacept (also known as ALX148), will have a wide therapeutic window to block the “don’t eat me” signal and “don’t activate T-cell” signal on cancer cells and will enhance the immune activation of broadly used anti-cancer agents through combination treatment strategies.

PT217: Phanes Therapeutics

PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47). It is developed by phanes therapeutics and is currently being tested in clinical studies for the treatment of small cell lung cancer (SCLC), gastroenteropancreatic neuroendocrine carcinoma, and others.

PT217 has received orphan drug designation for SCLC, and fast track designation for extensive-stage SCLC (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor from FDA.

Note: Detailed emerging therapies assessment will be provided in the final report....

Note: Emerging drug list is indicative, the full list will be given in the final report....

Unlock the Secrets of Market Trends: Request Your Comprehensive Sample Page and See the Analysis Behind the Numbers @ CD47 Inhibitors Drug Clinical Trials

CD47 Inhibitors Market Outlook 

The market for CD47 inhibitors is expected to grow significantly in the coming years due to the expected launch of late-stage pipeline drugs such as evorpacept, the increasing number of CD47 inhibitors in clinical trials, and the increasing collaborations between the companies for CD47 inhibitor drug development.

At present, there are no approved CD47 inhibitors in the market.

There is an urgent need for novel therapies for patients relapsing post-PARP inhibitors. CD47 is an attractive target due to its overexpression in ovarian cancer, particularly under PARPi treatment.

Recent studies suggested that combining osimertinib (third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI)) with CD47 blockade could be a promising strategy to improve outcomes in EGFR-mutant non-small cell lung cancer (NSCLC). This finding also indicates that CD47 upregulation might play a role in resistance to osimertinib.

Gilead Sciences' investigational anti-CD47 monoclonal antibody, Magrolimab, had garnered significant attention with FDA designations like Breakthrough Therapy designation for the treatment of Myelodysplastic Syndrome (MDS). However, recently, all Magrolimab studies in MDS and Acute Myeloid Leukemia (AML) were halted by the FDA due to observed futility and an elevated risk of mortality.

Several key players, including ALX Oncology, Phanes Therapeutics, Shattuck Labs and others, are involved in developing drugs for CD47 inhibitors for various indications such as gastric/gastroesophageal junction cancer, head and neck cancer, small cell lung cancer and others. 

Regulatory agencies such as the FDA have assigned a range of designations, such as fast track and orphan drug designation, to incentivize pharmaceutical companies to pursue the development of CD47 inhibitors.

Overall, this is an exciting new class of agents with great potential for development. Progress of current studies over the next few years will lead to a better understanding of CD47 inhibitors and define their role in the therapy of cancer.

Curious About the Market’s Future? Download Your Sample Page Now to Explore the In-Depth Insights Powering Industry Changes @ CD47 Therapeutics Market

CD47 inhibitors Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging CD47 inhibitors expected to be launched in the market during 2020–2034.

CD47 Inhibitors Pipeline Development Activities

The CD47 Inhibitors pipeline report provides insights into different CD47 Inhibitors clinical trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics. 

The presence of multiple drugs under different stages is expected to generate immense opportunity for CD47i market growth over the forecasted period.

CD47 Inhibitors Pipeline development activities

The CD47 Inhibitors clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for CD47 inhibitors emerging therapies. 

The increasing strategic collaborations among major market players to enhance the growth of their pipeline products are anticipated to drive market expansion. For example, in February 2021, Arch Oncology collaborated with Merck for the development of an anti-CD47 antibody, AO-176 in combination with KEYTRUDA (pembrolizumab) in patients with selected solid tumors.  

KOL Views on CD47 Inhibitors

To keep up with current and future market trends, we take industry experts’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on CD47 inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

DelveInsight’s analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM.

Their opinion helps understand and validate current and emerging therapy treatment patterns or CD47 inhibitors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

CD47 Inhibitors Report Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Key Updates on CD47 Inhibitors

• During ASCO 2024, ALX Oncology presented the results of a Phase 2 study of evorpacept, cetuximab, and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer.
• In August 2023, ALX Oncology dropped trials for two of its anti-CD47 programs (ASPEN-02 and ASPEN-05) which were evaluating the efficacy of its CD47 inhibitor, evorpacept, after disappointing efficacy findings.
• In June 2024, SL-172154 received Orphan Drug Designation from FDA in Acute Myeloid Leukemia.

Update is not exhaustive, will be provided in the final report...

Scope of the CD47 Inhibitors Market Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of CD47 inhibitors, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the CD47 inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM CD47 inhibitors market.

CD47 inhibitors Market Report insights

• CD47 Targeted Patient Pool
• CD47 Inhibitors Therapeutic Approaches
• CD47 Inhibitors Pipeline Analysis
• CD47 Inhibitors Market Size and Trends
• Existing and future Market Opportunity 

CD47 inhibitors Market Report key strengths

• Eleven years Forecast
• The 7MM Coverage 
• Key Cross Competition 
• CD47 Inhibitors Drugs Uptake
• Key CD47 Inhibitors Market Forecast Assumptions

CD47 inhibitors Market Report assessment

• Current CD47 Inhibitors Treatment Practices
• CD47 Inhibitors Unmet Needs
• CD47 Inhibitors Pipeline Product Profiles
• CD47 Inhibitors Market Attractiveness
• Qualitative Analysis (SWOT)
• CD47 Inhibitors Market Drivers
• CD47 Inhibitors Market Barriers

Key Questions Answered In The CD47 Inhibitors Market Report:

• What was the CD47 inhibitor total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for CD47 inhibitors?
• Which drug segment accounts for maximum CD47 inhibitor sales?
• What are the pricing variations among different geographies for approved therapies?
• How the reimbursement landscape has for CD47 inhibitors evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?

• What are the risks, burdens, and unmet needs of treatment with CD47 inhibitors? What will be the growth opportunities across the 7MM for the patient population of CD47 inhibitors?

• What are the key factors hampering the growth of the CD47 inhibitors market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for CD47 inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to buy CD47 Inhibitors Market Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the CD47 inhibitors Market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Click here to view the latest blogs:

• J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug

Visit delveinsight latest blogs @ Latest Delveinsight Blogs